Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Pharma's Future Leaders -- Or Its Pallbearers
- Given the challenges facing Big Pharma -- expiring patents, waning drug pipelines, the imploding blockbuster model, and increasing political pressure on its marketing practices -- it's hard not to wonder sometimes just who in their right minds would want to lead its giant but fragile companies over the next decade...
- Blog posts 2008-06-24
- Europeans Chew on Pfizer's Chantix as Americans Turn Away
- Pfizer's smoking cessation product, Chantix, seems to be going down the path of Exubera in the U.S.: Sales were down 49 percent to $96 million in America, and down globally by 24 percent to $182 million, making it a marginal drug for Pfizer. But in foreign territories,...
- Blog posts 2008-10-22
- Pharma Roundup: Pfizer's Acquisition Plans, Prasugrel's Big Day, and More
- Pfizer wants acquisitions, big and small. Prasugrel has a date with the FDA. New Year's blog feature bonanza. Farewell, Pharmalot. by John Maas
- Blog posts 2009-01-05
- Pharmalot's Ed Silverman: The Exit Interview
- On Monday, Pharmalot's Ed Silverman shocked the pharmaceutical business by returning from vacation and announcing that his blog was no more. Over the past two years, Pharmalot grew into the premier supplier of aggregated drug news and a formidable producer of original content even BNET took the Pharmalot feed. In...
- Blog posts 2009-01-06
Additional Resources
- Ed Silverman to Reopen Pharmalot Next Week
- Ed Silverman will re-open Pharmalot next week, according to the MM&M. The news will be greeted with whoops of joy in Pharma-land and mixed feelings among drug bloggers who, since January, had been enjoying the vacuum his departure created. It also raises the question of why Elsevier saw fit to...
- Blog posts 2009-10-09
- Pharma Roundup: Pfizer's Acquisition Plans, Prasugrel's Big Day, and More
- Pfizer CEO seeks big acquisition — In a much-discussed comment to the Financial Times, Pfizer's CEO Jeff Kindler revealed his aspirations for revenue-boosting deals, large and small. As the Health Blog points out, the takeaway here is Kindler's apparent willingness to pursue old-fashioned big acquisitions, at a time when most...
- News items 2009-08-07
- Schering's CEO, a Failed Trial and $16 Million
- Forbes' Matthew Herper and Michael Maiello have just jumped on a subject we alluded to -- perhaps too obliquely -- a few weeks back in discussing the eye-popping $30 million Schering-Plough CEO Fred Hassan pulled down in 2007. Not only did Schering post a $1.5 billion loss that year, it...
- Blog posts 2008-05-20
- Pfizer and Chantix: From Bad to Worse
- Much as I suspected when I first wrote about Pfizer's attempts to minimize potentially serious neurological side effects of its smoking-cessation drug Chantix, the drugmaker's stonewalling tactics have simply made a bad situation worse. To wit: John Spangler, director of Tobacco Intervention Programs at Wake Forest University,...
- Blog posts 2008-06-17
- Journal Uses Out-of-Date Info to Bash Merck's Gardasil
- Pharmalot and the Wall Street Journal both used outdated information in items they published on Merck's Gardasil today. That's a shame, because having accurate, up-to-date information is crucial in sorting fact from squeamishness about the controversial HPV vaccine that is now mandatory for many schoolgirls. The WSJ and Pharmalot pointed...
- Blog posts 2008-11-12
- How Pharma Stacks the Deck with Medical Journals
- Some once-friendly ghosts may be getting Merck in trouble all over again. The ethereal beings in question are ghostwriters -- the nameless, faceless freelancers paid by drug companies to draft up medical review papers, usually well before they're even seen by the academic researchers who will eventually...
- Blog posts 2008-04-15
- Alabama court gives upset victory to pharma
- In a turnabout victory for drugmakers, the Alabama Supreme Court has overturned $274 million in jury verdicts. The juries had awarded money to the state, based on accusations that AstraZeneca, Novartis and GlaxoSmithKline had overcharged Medicaid for their drugs. But Alabama's top court essentially said that if the state were...
- News items 2009-10-19
- EMEA links 24th PML case to Tysabri
- European regulators offer yet another update on Tysabri-linked cases of progressive multifocal leukoencephalopathy: The grand total is now 24, up from 23 last week and just 13 some six weeks ago. Of those 24 patients, four died. The numbers are coming thick and fast now because the European Union is...
- News items 2009-10-30
- Drugmakers vow battle against House bill
- With the U.S. House version of healthcare reform still moving forward, drugmakers are digging in. They're pledging to fight the House proposals it considers unfriendly to the industry, working closely with lobbyists and pushing back against sales projections that contradict industry talking points. AstraZeneca CEO David Brennan photo--who's also the...
- News items 2009-11-16
- Marketing Trumps Science in Vytorin Scandal
- In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year. ...
- Blog posts 2008-04-01
- Comparative Effectiveness: Putting Medicine Under a Microscope
- Most people don't know it, but hard evidence as to which medical treatments actually work best is in awfully short supply here in the U.S. The growing scandal over the expensive cholesterol drug Vytorin, which appears to be no more effective than older, cheaper statin drugs, is just the latest...
- Blog posts 2008-04-01
- Vytorin Update: Big Pharma Strikes Back
- The saga over Vytorin, the expensive cholesterol pill that may be no better than older, cheaper "statin" drugs, has come to a familiar pass: The manufacturer backlash. Merck and Schering-Plough, the makers of Vytorin, saw their stocks crushed the day after cardiologists trashed the multi-billion-dollar drug at...
- Blog posts 2008-04-03
- Comparative Effectiveness: Putting Medicine Under a Microscope
- Most people don't know it, but hard evidence as to which medical treatments actually work best is in awfully short supply here in the U.S. The growing scandal over the expensive cholesterol drug Vytorin, which appears to be no more effective than older, cheaper statin drugs, is just the latest...
- Blog posts 2008-04-01
- Marketing Trumps Science in Vytorin Scandal
- In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year. ...
- Blog posts 2008-04-01
- Vytorin Update: Big Pharma Strikes Back
- The saga over Vytorin, the expensive cholesterol pill that may be no better than older, cheaper "statin" drugs, has come to a familiar pass: The manufacturer backlash. Merck and Schering-Plough, the makers of Vytorin, saw their stocks crushed the day after cardiologists trashed the multi-billion-dollar drug at...
- Blog posts 2008-04-03
- Pfizer Leads in Layoffs While Drug Prices Soar
- Big Pharma continues to lend new meaning to the phrase "doing more with less," because while the industry seems to get smaller every day, drugmakers are still pushing through big price increases on their leading products. Over at Pharmalot, Ed Silverman provides a helpful roundup tracking the...
- Blog posts 2008-04-10
- << Previous
- page 1 of 1
- Next >>
